324 related articles for article (PubMed ID: 23383287)
1. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.
Christiansson L; Söderlund S; Svensson E; Mustjoki S; Bengtsson M; Simonsson B; Olsson-Strömberg U; Loskog AS
PLoS One; 2013; 8(1):e55818. PubMed ID: 23383287
[TBL] [Abstract][Full Text] [Related]
2. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.
Pinton L; Solito S; Damuzzo V; Francescato S; Pozzuoli A; Berizzi A; Mocellin S; Rossi CR; Bronte V; Mandruzzato S
Oncotarget; 2016 Jan; 7(2):1168-84. PubMed ID: 26700461
[TBL] [Abstract][Full Text] [Related]
3. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.
Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL
J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
Noman MZ; Desantis G; Janji B; Hasmim M; Karray S; Dessen P; Bronte V; Chouaib S
J Exp Med; 2014 May; 211(5):781-90. PubMed ID: 24778419
[TBL] [Abstract][Full Text] [Related]
5. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.
Mumprecht S; Schürch C; Schwaller J; Solenthaler M; Ochsenbein AF
Blood; 2009 Aug; 114(8):1528-36. PubMed ID: 19420358
[TBL] [Abstract][Full Text] [Related]
6. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.
Ruan WS; Feng MX; Xu J; Xu YG; Song CY; Lin LY; Li L; Lu YQ
Front Immunol; 2020; 11():1299. PubMed ID: 32719675
[No Abstract] [Full Text] [Related]
7. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
8. Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.
Giallongo C; Parrinello N; Tibullo D; La Cava P; Romano A; Chiarenza A; Barbagallo I; Palumbo GA; Stagno F; Vigneri P; Di Raimondo F
PLoS One; 2014; 9(7):e101848. PubMed ID: 25014230
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.
Choi DC; Tremblay D; Iancu-Rubin C; Mascarenhas J
Ann Hematol; 2017 Jun; 96(6):919-927. PubMed ID: 28062906
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
[TBL] [Abstract][Full Text] [Related]
11. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
12. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
13. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
[TBL] [Abstract][Full Text] [Related]
14. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.
Christiansson L; Söderlund S; Mangsbo S; Hjorth-Hansen H; Höglund M; Markevärn B; Richter J; Stenke L; Mustjoki S; Loskog A; Olsson-Strömberg U
Mol Cancer Ther; 2015 May; 14(5):1181-91. PubMed ID: 25761894
[TBL] [Abstract][Full Text] [Related]
15. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling.
Arkhypov I; Özbay Kurt FG; Bitsch R; Novak D; Petrova V; Lasser S; Hielscher T; Groth C; Lepper A; Hu X; Li W; Utikal J; Altevogt P; Umansky V
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113897
[TBL] [Abstract][Full Text] [Related]
16. The blockade of PD-1/PD-L1 pathway promotes the apoptosis of CD19
Wang Z; Tan F
Scand J Immunol; 2020 Feb; 91(2):e12836. PubMed ID: 31598989
[TBL] [Abstract][Full Text] [Related]
17. Granulocytic myeloid-derived suppressor cells inhibit T follicular helper cells during experimental Schistosoma japonicum infection.
Zhang Y; Wu Y; Liu H; Gong W; Hu Y; Shen Y; Cao J
Parasit Vectors; 2021 Sep; 14(1):497. PubMed ID: 34565440
[TBL] [Abstract][Full Text] [Related]
18. [Effect of PD-L1 blockade on function of dendritic cells derived from chronic myelocytic leukemia].
Wang CY; Zhang LS; Tian FQ; Huang R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1146-9. PubMed ID: 18928614
[TBL] [Abstract][Full Text] [Related]
19. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
[TBL] [Abstract][Full Text] [Related]
20. Increased, but Functionally Impaired, CD14(+) HLA-DR(-/low) Myeloid-Derived Suppressor Cells in Psoriasis: A Mechanism of Dysregulated T Cells.
Soler DC; Young AB; Fiessinger L; Galimberti F; Debanne S; Groft S; McCormick TS; Cooper KD
J Invest Dermatol; 2016 Apr; 136(4):798-808. PubMed ID: 26807516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
